Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types.
Spanò V, Rocca R, Barreca M, Giallombardo D, Montalbano A, Carbone A, Raimondi MV, Gaudio E, Bortolozzi R, Bai R, Tassone P, Alcaro S, Hamel E, Viola G, Bertoni F, Barraja P. Spanò V, et al. Among authors: barreca m. J Med Chem. 2020 Oct 22;63(20):12023-12042. doi: 10.1021/acs.jmedchem.0c01315. Epub 2020 Oct 11. J Med Chem. 2020. PMID: 32986419 Free PMC article.
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
Barreca M, Spanò V, Montalbano A, Cueto M, Díaz Marrero AR, Deniz I, Erdoğan A, Lukić Bilela L, Moulin C, Taffin-de-Givenchy E, Spriano F, Perale G, Mehiri M, Rotter A, P Thomas O, Barraja P, Gaudêncio SP, Bertoni F. Barreca M, et al. Mar Drugs. 2020 Dec 4;18(12):619. doi: 10.3390/md18120619. Mar Drugs. 2020. PMID: 33291602 Free PMC article. Review.
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas.
Barreca M, Spanò V, Rocca R, Bivacqua R, Abel AC, Maruca A, Montalbano A, Raimondi MV, Tarantelli C, Gaudio E, Cascione L, Rinaldi A, Bai R, Steinmetz MO, Prota AE, Alcaro S, Hamel E, Bertoni F, Barraja P. Barreca M, et al. Eur J Med Chem. 2022 Dec 5;243:114744. doi: 10.1016/j.ejmech.2022.114744. Epub 2022 Sep 8. Eur J Med Chem. 2022. PMID: 36242921
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G, Tarantelli C, Spriano F, Gaudio E, Cascione L, Mascia M, Barreca M, Arribas AJ, Licenziato L, Golino G, Ferragamo A, Pileri S, Damia G, Zucca E, Stathis A, Politz O, Wengner AM, Bertoni F. Sartori G, et al. Among authors: barreca m. Br J Haematol. 2024 Jan;204(1):191-205. doi: 10.1111/bjh.19218. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38011941
GPCR Inhibition in Treating Lymphoma.
Barreca M, Spanò V, Raimondi MV, Bivacqua R, Giuffrida S, Montalbano A, Cavalli A, Bertoni F, Barraja P. Barreca M, et al. ACS Med Chem Lett. 2022 Feb 15;13(3):358-364. doi: 10.1021/acsmedchemlett.1c00600. eCollection 2022 Mar 10. ACS Med Chem Lett. 2022. PMID: 38239337 Free PMC article.
New strategies to hit hematological cancers.
Barreca M, Bertoni F, Barraja P. Barreca M, et al. Eur J Med Chem. 2024 Apr 15;270:116350. doi: 10.1016/j.ejmech.2024.116350. Epub 2024 Mar 20. Eur J Med Chem. 2024. PMID: 38582688 No abstract available.
172 results